Research Article
Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
Table 1
Baseline characteristics.
| | | All patients () | PDS () | IDS () |
| | Age; mean (SD) | 61.5 (10.7) | 59.4 (31–86) | 62.5 (29–83) | | WHO performance status, number (%) | | | | | 0 | 310 (45.0) | 122 (53.7) | 188 (40.7) | | 1 | 218 (31.6) | 63 (27.7) | 155 (33.5) | | 2 | 53 (7.7) | 13 (5.6) | 40 (8.7) | | 3 | 9 (1.3) | 2 (0.1) | 7 (1.5) | | Missing | 99 (14.4) | 27 (11.9) | 72 (15.6) | | ASA-score, number (%) | | | | | 1 | 198 (28.7) | 62 (27.4) | 136 (29.4) | | 2 | 370 (53.7) | 119 (52.4) | 251 (54.2) | | 3 | 88 (12.8) | 35 (15.4) | 53 (11.5) | | Missing | 34 (4.9) | 11 (4.8) | 23 (4.9) | | FIGO stage, number (%) | | | | | IIIC | 543 (78.8) | 209 (92.1) | 334 (72.3) | | IV | 146 (21.2) | 18 (7.9) | 128 (27.7) | | Histologic type, number (%) | | | | | Serous | 502 (72.9) | 156 (68.7) | 346 (74.8) | | Mucinous | 24 (3.5) | 12 (5.3) | 12 (2.6) | | Endometrioid | 47 (6.8) | 29 (12.8) | 18 (3.9) | | Clear cell | 20 (2.9) | 11 (4.8) | 9 (2.0) | | Undifferentiated | 86 (12.5) | 12 (5.3) | 74 (16.1) | | Mixed/other | 10 (1.5) | 7 (3.0) | 3 (0.6) | | Histologic grade, number (%) | | | | | Well differentiated | 32 (4.6) | 15 (6.6) | 17 (3.7) | | Moderately differentiated | 103 (14.9) | 47 (20.7) | 56 (12.1) | | Poorly differentiated | 373 (54.1) | 141 (62.1) | 232 (50.2) | | Missing | 181 (26.3) | 24 (10.6) | 157 (34.0) | | CA 125 before treatment; median (range) | 908.0 (12–67448) | 807.5 (12–67448) | 1041 (15–42077) | | Ascites at surgery (ml); median (range) | 500 (0–70000) | 200 (0–12000) | 500 (0–70000) | | Cycles of chemotherapy | 6 (0–13) | 6 (0–9) | 6 (0–13) | | Type of chemotherapy | | | | | Carboplatin/paclitaxel | 641 (93) | 197 (87) | 444 (96) | | Multidrug without platinum | 10 (1.5) | 3 (1) | 7 (2) | | Single drug platinum | 27 (3.9) | 17 (8) | 10 (2) | | No chemotherapy received | 8 (1.2) | 8 (4) | 0 (0.0) | | Missing | 3 (0.4) | 2 (1) | 1 (0) |
|
|
